Evidence map›Paper›PMID 26541501›Full record

Trial reportThe American journal on addictions2015

Outcome expectations and associated treatment outcomes in motivational enhancement therapy delivered in English and Spanish.

Kelly Serafini, Suzanne Decker, Brian D Kiluk, Luis Añez, Manuel Paris, Tami Frankforter, Kathleen M Carroll

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The American journal on addictions, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kelly SerafiniDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
Suzanne DeckerDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
Brian D KilukDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
Luis AñezDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
Manuel ParisDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
Tami FrankforterDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
Kathleen M CarrollDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
Yale University · USVA Connecticut Healthcare System · US

Funding

FLORIDA NODE OF THE DRUG ABUSE CLINICAL TRIALS NETWORKU10DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI METSCH, LISA R, SZAPOCZNIK, JOSE · 2000 to 2015
$56.9M
The National Drug Abuse Treatment Clinical Trials NetworkU10DA013045 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LING, WALTER NMN · 1999 to 2015
$52.6M
CU PARTNERS: NY/LONG ISLAND REGIONAL NODEU10DA013035 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI NUNES, EDWARD V., ROTROSEN, JOHN P · 2001 to 2015
$47.6M
TSF to enhance treatment of cocaine dependenceP50DA009241 · NIDA · YALE UNIVERSITY · PI KOBER, HEDY · 1994 to 2018
$40.5M
The National Drug Abuse Treatment Clinical Trials Network (U10)U10DA015831 · NIDA · MC LEAN HOSPITAL (BELMONT, MA) · PI CARROLL, KATHLEEN M., WEISS, ROGER D. · 2002 to 2015
$28.8M
Delaware Valley Node of the Clinical Trials NetworkU10DA013043 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI WOODY, GEORGE EDWARD · 1999 to 2015
$25.8M
Clinical Trials Network: Southwest NodeU10DA015833 · NIDA · UNIVERSITY OF NEW MEXICO · PI MCCRADY, BARBARA S · 2002 to 2014
$19.9M
OREGON NODE - NATIONAL CLINICAL TRIALS NETWORKU10DA013036 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI MCCARTY, DENNIS · 1999 to 2010
$18.5M
CLINICAL TRIALS NETWORK: NEW ENGLAND NODEU10DA013038 · NIDA · YALE UNIVERSITY · PI CARROLL, KATHLEEN M. · 1999 to 2010
$17.3M
ROCKY MOUNTAIN REGIONAL CLINICAL TRIALS NODEU10DA013716 · NIDA · UNIVERSITY OF COLORADO DENVER/HSC DENVER · PI RIGGS, PAULA DEGRAFFENREID · 2000 to 2005
$12.7M
Research Training Fellowship in Substance use and Addiction (RTFSA)T32DA007238 · NIDA · YALE UNIVERSITY · PI BRIAN D. KILUK, ISMENE L. PETRAKIS · 1988 to 2026
$5.7M
NIDA NIH HHS 5T32DA007238-23NIDA NIH HHS L30 DA038218NIDA NIH HHS P50 DA009241NIDA NIH HHS P50DA09241NIDA NIH HHS T32 DA007238NIDA NIH HHS U10 DA013035NIDA NIH HHS U10 DA013036NIDA NIH HHS U10 DA013038NIDA NIH HHS U10 DA013043NIDA NIH HHS U10 DA013045NIDA NIH HHS U10 DA013716NIDA NIH HHS U10 DA013720NIDA NIH HHS U10 DA015831NIDA NIH HHS U10DA015831NIDA NIH HHS U10 DA015833NIDA NIH HHS U10 DA13035NIDA NIH HHS U10 DA13036NIDA NIH HHS U10 DA13038NIDA NIH HHS U10 DA13043NIDA NIH HHS U10 DA13045NIDA NIH HHS U10 DA13716NIDA NIH HHS U10 DA13720
6 · The paper itself

Abstract

BACKGROUND AND

objectivesThe relationship between patients' baseline expectations regarding treatment outcome and actual outcomes has not been widely studied within the field of substance use disorders. We hypothesized that outcome expectations would be unrelated to outcomes in a study investigating motivational enhancement therapy delivered in English (MET-E) consistent with our earlier work, and conducted exploratory analyses in a separate study that investigated the same treatment delivered in Spanish (MET-S).

methodsThese secondary analyses compared patient outcome expectations and substance use treatment outcomes in two large, multisite randomized controlled clinical trials that evaluated three sessions of MET-E or MET-S. The MET-E sample included 461 participants and the MET-S sample included 405 participants. Outcome expectations were measured by a single item regarding expectations about abstinence prior to initiating treatment.

resultsOutcome expectations were strongly associated with most substance use outcomes in the MET-S trial (but not in MET-E), even after controlling for severity of substance use at baseline. In MET-S, those who indicated that they were "unsure" that they would achieve abstinence during treatment submitted a greater percentage of drug-positive urine toxicology screens during the treatment period than those who were 'sure' they would achieve abstinence (F = 18.83, p < .001). DISCUSSION AND

conclusionsPatients' outcome expectations regarding the likelihood of abstinence may be an important predictor of drug use treatment outcomes among Spanish-speakers, but not necessarily for English-speakers. SCIENTIFIC SIGNIFICANCE: Individual differences and cultural factors may play a role in the association between outcome expectations and treatment outcomes.

Indexed as

AttitudeLanguageMotivational InterviewingAcculturationAdolescentAdultFemaleHispanic or LatinoHumansMaleMotivationSubstance-Related DisordersTreatment OutcomeYoung Adult

Identifiers

PMID26541501
PMCPMC4885684
OpenAlexW2163207515

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.